A novel deep intronic "SERPING1" variant as a cause of hereditary angioedema due to C1-inhibitor deficiency by Vatsiou, Sofia et al.
lable at ScienceDirect
Allergology International 69 (2020) 443e449Contents lists avaiAllergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i tOriginal ArticleA novel deep intronic SERPING1 variant as a cause of hereditary
angioedema due to C1-inhibitor deficiency
Sofia Vatsiou a, b, Maria Zamanakou a, Gedeon Loules a, Fotis Psarros c,
Faidra Parsopoulou a, b, Dorottya Csuka d, Anna Valerieva e, Maria Staevska e,
Grzegorz Porebski f, Krystyna Obtulowicz f, Markus Magerl g, Marcus Maurer g,
Matthaios Speletas b, Henriette Farkas d, Anastasios E. Germenis a, b, *
a CeMIA SA, Larissa, Greece
b Department of Immunology & Histocompatibility, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece
c Department of Allergology, Navy Hospital, Athens, Greece
d Hungarian Angioedema Reference Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
e Clinic of Allergy and Asthma, Medical University of Sofia, Sofia, Bulgaria
f Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland
g Department of Dermatology and Allergy, Charite - Universit€atsmedizin Berlin, Berlin, Germanya r t i c l e i n f o
Article history:
Received 8 October 2019
Received in revised form
29 November 2019
Accepted 23 December 2019
Available online 17 January 2020
Keywords:
C1-inhibitor deficiency
Hereditary angioedema
Intronic mutations
Next-generation sequencing
SERPING1 gene
Abbreviations:
ACMG, American College of Medical
Genetics and Genomics; ASSP, Alternative
Splice Site Predictor; AMP, Association for
Molecular Pathology; C1-INH, C1-inhibitor;
C1-INH-HAE, hereditary angioedema due to
C1-INH deficiency; CADD, Combined
Annotation Dependent Depletion;
GERP, Genomic Evolutionary Rate Profiling;
HSF, Human Splicing Finder; ISS, intronic
splicing silencer; NGS, next-generation
sequencing* Corresponding author. Department of Immunolo
ulty of Medicine, University of Thessaly, 3 Panepistim
issa, Greece.
E-mail address: agermen@med.uth.gr (A.E. Germe
Peer review under responsibility of Japanese Soci
https://doi.org/10.1016/j.alit.2019.12.009
1323-8930/Copyright © 2020, Japanese Society of Alle
licenses/by-nc-nd/4.0/).a b s t r a c t
Background: In about 5% of patients with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-
HAE) no mutation in the SERPING1 gene is detected.
Methods: C1-INH-HAE cases with no mutation in the coding region of SERPING1 after conventional
genotyping were examined for defects in the intronic or untranslated regions of the gene. Using a next-
generation sequencing (NGS) platform targeting the entire SERPING1, 14 unrelated C1-INH-HAE patients
with no detectable mutations in the coding region of the gene were sequenced. Detected variants with a
global minor allele frequency lower than the frequency of C1-INH-HAE (0.002%), were submitted to in
silico analysis using ten different bioinformatics tools. Pedigree analysis and examination of their
pathogenic effect on the RNA level were performed for filtered in variants.
Results: In two unrelated patients, the novel mutation c.-22-155G > T was detected in intron 1 of the
SERPING1 gene by the use NGS and confirmed by Sanger sequencing. All bioinformatics tools predicted
that the variant causes a deleterious effect on the gene and pedigree analysis showed its co-segregation
with the disease. Degradation of the mutated allele was demonstrated by the loss of heterozygosity on
the cDNA level. According to the American College of Medical Genetics and Genomics 2015 guidelines the
c.-22-155G > T was curated as pathogenic.
Conclusions: For the first time, a deep intronic mutation that was detected by NGS in the SERPING1 gene,
was proven pathogenic for C1-INH-HAE. Therefore, advanced DNA sequencing methods should be per-
formed in cases of C1-INH-HAE where standard approaches fail to uncover the genetic alteration.
Copyright © 2020, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).gy & Histocompatibility, Fac-
iou str., Biopolis, 41500, Lar-
nis).
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C1-INH-HAE (OMIM#106100) is a potentially fatal autosomal
dominant disease that manifests clinically with episodes of non-
pruritic and nonpitting swelling of the deeper layers of the skin or
mucosa.1 The disease is caused by mutations of the SERPING1 gene,
which encodes for C1-INH. SERPING1 is located on chromosome 11
and consists of 8 exons.2 Currently, 748 different disease-causing
SERPING1 variants have been published.3 However, invier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
S. Vatsiou et al. / Allergology International 69 (2020) 443e449444approximately 5% of C1-INH-HAE patients no causal mutation is
identified by standard mutational screening which is ordinarily
restricted to the coding exons and exon-intron boundaries of the
SERPING1 gene.4,5
Intronic sequences were initially assumed to be largely non-
functional and mutations located deep within introns (i.e., more
than100basepairs away fromexon-intron boundaries)were ignored
aspossiblecausesofhumandisease.However, genomicapproaches in
clinicallyorientedstudieshave identifiedmanydeep intronicvariants
with significant association to diseases, and intron functionality is
supported by several independent lines of evidence.6,7 Recently, Vaz-
Dragoetal.7havereviewed,between1983and2016,185deep intronic
mutations across 77 different disease-associated genes.
Hitherto, conventional methods for genotyping of C1-INH-HAE
patients did not allow the analysis of SERPING1 intronic regions.
Even when some introns are sequenced along with their upstream
and downstream exons, possible detection of deep intronic variants
is disregarded. Thus, no deep intronic variant has been reported in
association with C1-INH-HAE. To overcome some of the short-
comings of traditional approaches we recently developed a custom
next-generation sequencing (NGS) platform that allows analyzing
SERPING1 in its full length.8 Here, we use this platform for geno-
typing C1-INH-HAE patients with no detectable mutations in the
coding region of SERPING1, and we describe our results and their
relevance.
Methods
Study population
Fourteen patients (3 Greek, 2 Hungarian, 4 Polish, 3 Bulgarian, 2
German; 5 male, mean age 43 ± 17 years) diagnosed with type I C1-
INH-HAE, according to the criteria of the Hereditary Angioedema
International Working Group,9 but without SERPING1 mutations
after conventional molecular analysis, were initially enrolled in the
study. Pedigree analysis became feasible in one case. Three healthy
first degree relatives of the patient and three first degree relatives
with C1-INH-HAE were examined. Informed consent was obtained
from all patients and family members investigated, and the study
has been approved by the Ethics Committee of the Faculty of
Medicine, University of Thessaly.
Genetic analysis
Genomic DNA was extracted from peripheral blood with iPrep
PureLink DNA blood kit (Invitrogen, Carlsbad, CA, USA) according to
manufacturer's instructions. Conventional genotyping had been
performed by sequencing all SERPING1 translated regions and
intron-exon boundaries, long-range PCR and multiplex ligation-
dependent probe amplification (MLPA), as previously described.4
A custom NGS panel was designed by the Ion AmpliSeq Thermo
Fisher Scientific Designer, as previously described,8 covering the
whole SERPING1 gene (NM_000062.2) including its complete 50 and
30 untranslated regions, exonic and intronic regions (Chr11:
57,364,831e57,382,476; GRCh37). Coverage of 99.9% and 79.9% of
exonic and intronic regions of SERPING1was achieved, respectively.
Missing intronic regions were mainly those of introns 3, 4, and 6
(41,4%, 42,2% and 22,5%, respectively). Briefly, amplicon libraries
were prepared using the Ion AmpliSeq Library Kit 2.0 (Thermo
Fisher Scientific, Waltham, MA, USA) and Ion Xpress™ Barcode
Adapter 1e96 Kit (Thermo Fisher Scientific). Pooled, barcoded li-
braries were clonally amplified using the Ion OneTouch™ system
and Ion OT2 HI-Q Template kit (Thermo Fisher Scientific). Ion
sphere particles (ISPs) were enriched with the Dynabeads®
MyOne™ Streptavidin C1 Beads (Thermo Fisher Scientific) andwashed with the Ion OneTouch Wash Solution included in the kit
using the Ion One Touch ES system (Thermo Fisher Scientific). NGS
was performed on the Personal Genome Machine (PGM) using the
Ion PGM Hi-Q sequencing kit (Thermo Fisher Scientific) resulting in
a mean depth of coverage 20x. All procedures were performed
according to the manufacturer's instructions.
Torrent Suite 5.2 software was used for the analysis of NGS data.
Raw data were aligned to the complete SERPING1 gene of the hu-
man reference sequence hg19 (GRCh37), variant calling was per-
formed by the VariantCaller v.5.2 plug-in and coverage analysis by
the coverageAnalysis v.5.2.1.2 plug-in. Annotation of variants was
performed on Ion Reporter software v.5.2 (Thermo Fisher Scienti-
fic). The annotated variants were evaluated and visualized via
integrative genome viewer (IGV).
Variants that were present in the reference population data sets
[Genome Aggregation Database (gnomAD), Exome Aggregation
Consortium10 release 0.3 (ExAC Browser), Database of Single
Nucleotide Polymorphisms11 build 141 GRCh37.p13 (dbSNP)] at a
global minor allele frequency greater than that the frequency C1-
INH-HAE (<0.002%) were filtered out from the analysis.
Sanger sequencing was performed for the confirmation of novel
variants and family segregation study. The intron 1 of the SERPING1
gene was amplified by using the primers 50-CTGCACC-
CAAGCTTCCCCGTTCAC-30 and 50-CCCCGTCCCCCATCCCACAAG-3’.
The PCR was initiated at 94 C for 2 min, followed by denaturation
at 94 C for 45 s, annealing at 65 C for 45 s, and extension at 72 C
for 1 min for 30 cycles. The amplified products were sequenced
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) and analyzed in ABI 3730 DNA
Analyzer (Applied Biosystems, Foster City, USA). Data were evalu-
ated by the Sequencing Analyses software 5.2 (Applied Biosystems,
Foster City, California, USA).12
In silico analyses
The putative effect of filtered-in intronic mutations was evalu-
ated by using ten different bioinformatics analysis tools. Sequence
segments with and without corresponding changes in their se-
quences were submitted to five bioinformatics tools examining
potential splice effects: NNSPLICE,13 Netgene2,14 ASSP,15 FSPLICE
and HSF.16 All of them provide probability scores for the use of
potential donor and acceptor splice sites. Further assessment of the
pathogenicity was attempted by the use of 5 additional tools. The
CADD provides prediction of the functional impact of the observed
variants by integrating different functional aspects and diverse
annotations into a single outcome, namely the C-score17; the
Transcript-inferred Pathogenicity score (Trap score) evaluates a
single nucleotide variant's ability to cause disease by damaging the
final transcript18; DANN is a pathogenicity scoring methodology
based on deep neural networks19; GERP is a conservation score
calculated by quantifying substitution deficits across multiple
alignments of orthologues using the genomes of 35 mammals20;
finally, SpliceAid 2 bioinformatics foresee the splicing pattern
alteration and guide the identification of themolecular effect due to
the mutations.21
Transcriptional analysis
In order to further evaluate the function effect of the variant c.-
22-155G > T, whole blood was collected from the proband and his
three suffering family members carrying the mutation and being
heterozygous for the rs4926 (c.1438G > A) polymorphism. Mono-
nuclear cells were separated by a Ficoll gradient, and total RNAwas
extracted with phenol-chloroform, ethanol precipitated, and puri-
fied by guanidinium thiocyanate dissociation and isopropanol
S. Vatsiou et al. / Allergology International 69 (2020) 443e449 445precipitation.22,23 First-Strand cDNA was synthesized from 1 mg
RNA in 25 ml reactions with 25 mM Primer random p[dN]6 (Roche),
10 mM dNTPs (Invitrogen, Carlsbad, CA, USA) and 200 U/mL M-MLV
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) employed in
72 C for 2 min, 42 C for 75 min and 65 C for 10 min.
In the produced cDNA, a fragment from exons 6e8 was ampli-
fied, sequenced and compared to the gDNA sequence. The forward
50AACTCAGTTATAAAAGTGCCCATGATGAAT3’24 and the reverse
50CCCTTTTGGTGGATAGCG-3’25 primers were used. The amplifica-
tion of the cDNA was performed using 10 pmol of each primer and
35 cycles in a Veriti® Thermal Cycler (Applied Biosystems, Foster
City, USA), comprising of 1 min at 94 C,1 min at 55 C, and 1min at
72 C, followed by a final extension of 10min at 72 C. The amplified
products were sequenced and analyzed, as described above.Table 1
Filtered out intronic mutations presenting in the Genome Aggregation Databas
Locus Genotype Coding
chr11:57365895 G/A c.51 þ 101G > A
chr11:57366405 C/CGT c.51 þ 625_51 þ 626dupTG
chr11:57366656 C/T c.52e696C > T
chr11:57367222 C/T c.52e130C > T
chr11:57369008 C/G c.551-500C > G
chr11:57369013 A/C c.551-495A > C
chr11:57369353 A/G c.551-155A > G
chr11:57369730 G/A c.685 þ 88G > A
chr11:57370742 C/T c.685 þ 1100C > T
chr11:57371911 G/T c.686-1572G > T
chr11:57371918 G/A c.686-1565G > A
chr11:57372526 A/G c.686e957A > G
chr11:57373304 A/G c.686-179A > G
chr11:57374280 G/A c.1029 þ 260G > A
chr11:57374332 T/C c.1029 þ 312T > C
chr11:57374871 C/G c.1029 þ 851C > G
chr11:57374946 G/T c.1029 þ 926G > T
chr11:57375463 G/C c.1029 þ 1443G > C
chr11:57375517 A/G c.1029 þ 1497A > G
chr11:57376130 T/C c.1029 þ 2110T > C
chr11:57376131 A/G c.1029 þ 2111G > A
chr11:57377215 G/C c.1030-1975G > C
chr11:57377676 CT/C c.1030-1513delT
chr11:57377968 A/G c.1030e1222A > G
chr11:57377992 G/T c.1030-1198G > T
chr11:57378325 C/T c.1030-865C > T
chr11:57379170 A/G c.1030-20A > G
chr11:57381263 T/C c.1250-538T > C
chr11:57381519 T/C c.1250-282T > C
Table 2
Bioinformatic analysis of the six filtered-in intronic mutations.
Variant NNSPLICEy Netgene2z ASSPx FSPLICE¶ HSFk
c.-22-155G > T D:0.96 D:0.79 D:0.46 D:10.16 New in
c.551-156A > G NI NI NI NI Creatio
c.686e1488_686-1487insT NI NI NI NI Creatio
c.686e1335T > A NI NI NI NI Alterat
c.686e1333A > T NI NI NI NI NI
c.1250-154C > G¶¶ NI NI NI NI Creatio
NI, No impact; NP, Not provided; D, new donor; ISS, Intronic splicing silencer; ISE, Intro
y Range 0e1, with minimum score for 50 and 30 splice site 0.4 (www.fruitfly.org/seq_t
z Confidence range 0.5e0.95 (www.cbs.dtu.dk/services/NetGene2/).
x Confidence range 0e1, false splice site cutoff for acceptor sites: 2.2, false splice site cut
¶ Acceptor site threshold: 4.175, donor site threshold: 6.099 (www.softberry.com/ber
k www.umd.be/HSF/HSF.shtml.
# Range 10e30 (cadd.gs.washington.edu).
yy Range 0e1 (http://trap-score.org/Search?version¼v2).
zz Range 0e1.
xx e12.3 to 6.17.
¶¶ Observed in 2 patients (trans with the c.-22-155G > T variant) and one healthy memVariant curation
The interpretation of sequence variants was based on the
criteria established by the ACMG and the AMP.26 Data from our
previous study8 in regard with the presence of variants in healthy
individuals were used to this aim.
Results
Apart from the known polymorphisms rs28362944 and rs4926,
NGS genotyping of our C1-INH-HAE patients confirmed the absence
of disease-causing SERPING1 exonicmutations. However, 35 different
intronicmutationswere revealed in these patients, 29 of whichwere
filtered out as their global minor allele frequency was greater thane (gnomAD) with a global minor allele frequency greater than 0.002%.
dbSNP Intron Frequency (%)
rs28362945 2 12.56
rs3054018 2 38.99
rs1005511 2 39.51
rs1005510 2 38.72
rs28362947 3 22.03
rs28362948 3 22.03
rs2936694 3 36.84
rs11229063 4 22.24
rs78364821 4 22.52
rs28362949 4 22.08
rs28362950 4 22.42
rs28362951 4 22.19
rs189335964 4 0.1068
rs191053716 6 0.1356
rs11603020 6 22.79
rs11229066 6 22.79
rs11229067 6 22.79
rs78624400 6 22.82
rs17661117 6 0.6972
rs2454659 6 61.20
rs138770460 6 22.7
rs151035150 6 1.1044
rs1184255008 6 0.003227
rs3824988 6 22.78
rs2508443 6 32.92
rs2511989 6 38.14
rs2511988 6 61.09
rs10896631 7 22.76
rs1557522 7 30.64
CADD# Trap scoreyy DANNzz GERP RSxx
tronic cryptic donor site 21.2 0.686 0.9507 1
n of an ISE 1.427 0.103 0.3543 NP
n of an ISE NP NP NP 0.0435
ion of an ISS/Creation of an ISE 0.131 0.078 0.1134 1.335
0.969 0.012 0.1669 1.875
n of an ISE 3.911 0.122 0.5833 0.3333
nic splicing enhancer.
ools/splice.html).
off for donor sites: 4.5 (Alternative Splice Site Predictor: wangcomputing.com/assp/).
ry.phtml?topic¼fsplice&group¼programs&subgroup¼gfind).
ber of the studied family.
Fig. 1. Pedigree analysis of a C1-INH-HAE family carrying the deep intronic c.-22-155G > T variant. All examined suffering members of the family (III.2, III.4, III.6, IV.1) ecarriers of
the c.-22-155G > Te were heterozygous for the rs4926 (c.1438G > A) polymorphism, while all examined unaffected members (II.3, III.1, III.7) were homozygous for the wild type of
this polymorphism.
Fig. 2. cDNA and gDNA sequencing of one of the patients (III.6) carrying the c.-22-155
G > T variant and the rs4926 G > A polymorphism. Sequencing of the amplified cDNA
demonstrate that while in the gDNA the two alleles (G/A) of the rs4926 are equally
represented, in the cDNA only one allele (G) is present.
S. Vatsiou et al. / Allergology International 69 (2020) 443e4494460.002% (Table 1). Four out of the remaining 6 variants were unre-
ported (novel), and 2 were reported once in global databases.
Only one of the six filtered-in variants, the novel variant c.-22-
155G > T located in intron 1 of the SERPING1 gene
(chr11:57,365,567), was predicted as pathogenic by all used bioin-
formatics tools (Table 2). Moreover, this variant was also the only
one that was detected in two unrelated C1-INH-HAE Greek pa-
tients, i.e. with a frequency 14.3% among the cohort of our C1-INH-
HAE patients without any mutation in the exonic region of the
gene, while it was also undetectable in our healthy control group.8
Assuming a 5% frequency of C1-INH-HAE patients with no causal
mutation identified in the coding exons and exon-intron bound-
aries of the SERPING1 gene,4,5 the estimated frequency of this
variant among C1-INH-HAE patients is 0.7%. Thus, the c.-22-
155G > T variant was the only one that was further studied.
Pedigree analysis revealed that the c.-22-155G > T variant co-
segregated with C1-INH-HAE in all of the 4 analyzed patients
belonging to two generations, while it was absent from all of the 3
healthy family members whowere also analyzed (Fig. 1). Examined
patients were of 8, 40, 44 and 45 (the proband, III.2) years-of-age
with an age at disease onset of 8, 7, 24 and 13 years, and a mean
frequency of attacks (mainly cutaneous) 2, 5, 14 and 5 per year,
respectively. Their antigenic C1-INH concentration at diagnosis was
varying from 4% to 40% of the reference. Information about the
other suffering members of the family was unobtainable since they
are immigrants in Australia. The fifth, unrelated patient examined
was a man of 45 years-of-age without family history of angioedema
presenting with rare cutaneous attacks since the age of 25 years. No
other member of his family was available for analysis.
Further bioinformatic analysis with the use of SpliceAid 2 tool
showed that the c.-22-155G > T variant alters the transcriptional
motif recognized by hnRNP H1, hnRNP H2, hnRNP F and hnRNP H3
transcriptional factors preventing their binding in the corre-
sponding gene region.Transcript analysis supported the above indications of the dele-
terious effect of the c.-22-155G > T variant. By this approach loss of
heterozygositywasdemonstrated for the exon8 rs4926 (c.1438G>A)
polymorphism located in the same allele with the c.-22-155G > T
variant. More specifically, as it is shown in Figure 1, in the gDNA, all
Table 3
The 49 reported intronic mutations in SERPING1 gene associated with C1-INH-HAE. The majority of them are located in the donor and acceptor site or a few (up to 5) nu-
cleotides from these regions. Only the c.1029 þ 84G > A mutation is located 84 nucleotides from the acceptor site.
Mutation Intron Chromosome position dbSNP References
c.-22-2A > C 1 chr11:57365720 Aabom et al., 201733
c.-22-2A > G 1 chr11:57365720 Bygum et al., 201134; Xiong et al., 20156
c.-22-1G > A 1 chr11:57365721 Verpy et al., 199635; G€osswein et al., 200836; Xiong et al., 20156;
Duponchel et al., 200637; Andrejevic et al., 201538
c.51þ6T > G 2 chr11:57365800 Lopez-Lera et al., 201139
c.51þ5G > A 2 chr11:57365799 Verpy et al., 199635; Duponchel et al., 200637; Xiong et al., 20156
c.51 þ 1G > T 2 chr11:57365795 Yamamoto et al., 201240; Cagini et al., 201641
c.51 þ 1G > A 2 chr11:57365795 rs1470120365 G€osswein et al., 200836; Pappalardo et al., 20084; Kalmar et al., 200342; Xiong et al., 20156
c.51 þ 2T > C 2 chr11:57365796 Cagini et al., 201641
c.51 þ 3A > G 2 chr11:57365797 Roche et al., 200543; Pappalardo et al., 20084; Duponchel et al., 200637
c.522A > G 2 chr11:57367350 Pappalardo et al., 20084; Xiong et al., 20156
c.52e1 G > A 2 chr11:57367351 rs886041353 G€osswein et al., 200836; Xiong et al., 20156
c.550þ1G > A 3 chr11:57367851 Kalmar et al., 200342; Xiong et al., 20156
c.550þ2T > C 3 chr11:57367852 Roche et al., 2005;43
c.550 þ 5G > C 3 chr11:57367855 Roche et al., 200543; Xiong et al., 20156
c.550 þ 5G > A 3 chr11:57367855 rs1314284778 Roche et al., 200543; Xiong et al., 20156
c.551-2delA 3 chr11:57369506 Roche et al., 2005;43
c.551-1G > A 3 chr11:57369507 Speletas et al., 20155
c.551e2A > G 3 chr11:57369506 G€osswein et al., 200836; Grodecka et al., 201744
c.551e3 C > G 3 chr11:57369505 G€osswein et al., 200836
c.5515 T > A 3 chr11:57369503 Pappalardo et al., 20084
c.685 þ 31G > A 4 chr11: 57369673 rs751335805 Suffritti et al., 201445
c.685 þ 1G > T 4 chr11:57369643 Pappalardo et al., 20084; Xiong et al., 20156
c.685 þ 1 G > A 4 chr11:57369643 rs113263597 G€osswein et al., 200836; Xiong et al., 20156
c.685 þ 2T > A 4 chr11:57369644 Colobran et al., 201446
c.685 þ 2T > G 4 chr11:57369644 Pappalardo et al., 20084; Xiong et al., 20156
c.68612 A > G 4 chr11: 57373471 Pappalardo et al., 20084; Grodecka et al., 201744; Andrejevic et al., 201538
c.686-3C > G 4 chr11:57373480 Roche et al., 200543; Xiong et al., 20156
c.889 þ 1 G > T 5 chr11:57373687 G€osswein et al., 200836; Xiong et al., 20156
c.889 þ 2T > C 5 chr11:57373688 Roche et al., 200543; Xiong et al., 20156
c.889 þ 3A > T 5 chr11:57373689 Johnsrud et al., 201547
c.890-14C > G 5 chr11: 57373867 Speletas et al., 20155
c.890-2A > G 5 chr11: 57373879 Bowen et al., 200112; Xiong et al., 20156
c.890-1G > A 5 chr11: 57373880 Sekijima et al., 200448; Xiong et al., 20156
c.1029 þ 1 G > T 6 chr11:57374021 Siddique et al., 199149; Xiong et al., 20156
c.1029 þ 1 G > A 6 chr11:57374021 G€osswein et al., 200836; Xiong et al., 20156
c.1029 þ 84G > A 6 chr11:57374104 rs118132731 Pappalardo et al., 20084
c.1029 þ 3_
c.1029 þ 6 del4bp
6 chr11:57374023 G€osswein et al., 200836
c.1029 þ 4 delA 6 chr11:57374024 Bygum et al., 201134
c.1030e1 G > A 6 chr11:57379189 Speletas et al., 20155
c.1030e1 G > C 6 chr11:57379189 G€osswein et al., 200836; Verpy et al., 199635; Xiong et al., 20156
c.1249 þ 1G > C 7 Chr11: 57379410 Lopez-Lera et al., 201139
c.1249 þ 1G > A 7 Chr11: 57379410 rs112565881 G€osswein et al., 200836; Xiong et al., 20156
c.1249 þ 2T > A 7 Chr11: 57379411 Kawachi et al., 199850; Xiong et al., 20156
c.1249 þ 2delT 7 Chr11: 57379411 Roche et al., 2005;43
c.1249 þ 5G > T 7 Chr11: 57379414 Pappalardo et al., 20084; Grodecka et al., 201744
c.1249 þ 5G > A 7 Chr11: 57379414 Colobran et al., 201725; Grodecka et al., 201744
c.1250e13 G > A 7 chr11: 57381788 G€osswein et al., 200836; Kesim et al., 201151
c.1250-1G > A 7 chr11: 57381800 Aabom et al., 201733
c.1250e2 A > G 7 chr11: 57381799 G€osswein et al., 200836
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wereheterozygous for the rs4926 (c.1438G>A)polymorphism,while
all unaffected members were homozygous for the wild type. Inter-
estingly, in thecDNA,all patientswere foundhomozygous for thewild
type eonly one allele (G) is presente indicating that the mRNA from
the mutated allele is probably degraded (Fig. 2).
According to the ACMG-AMP 2015 guidelines26 the pathoge-
nicity potential of the c.-22-155G > T variant is “pathogenic” based
on: (a) The strong segregation data. The variant co-segregates with
disease in multiple affected family members in a gene definitively
known to cause the disease (PP1 criterion used as strong evidence).
(b) The absence of the variant from controls in Exome Sequencing
Project, 1000 Genomes Project, or Exome Aggregation Consortium
(PM2). (c) The observation of the variant in two unrelated probands
with the same phenotype, and its absence in controls (PS4). (d)
Prediction bymultiple bioinformatics tools that the variant causes adeleterious effect on the gene (PP3). (e) The patient's phenotype
and family history is highly specific for the disease (PP4). (f) In vitro
functional studies support a damaging effect on the gene (PS3).
Based on the available criteria (BS2, BS4, BP4, BP5) the remaining
intronic variants detected in our C1-INH-HAE patients were clas-
sified as “benign” or “likely benign”.
Discussion
To identify missing noncoding variants in C1-INH-HAE cases, we
sequenced the SERPING1 locus in 14 patients. In two of them, we
detected a novel deep intronic variant (c.-22-155G > T) which was
classified as pathogenic, according to ACMG-AMP 2015 guide-
lines.26 In recent years, increasing numbers of deep intronic vari-
ants located at least 100 bp from the nearest canonical splice site,
have been reported and their role in human diseases has been
Fig. 3. Graphical presentation of the impact of the c.-22-155G > T variant according to bioinformatics analysis. The variant is predicted to form an alternative donor site leading to a
modified mutant RNA longer (>372 bp) than the wild type.
S. Vatsiou et al. / Allergology International 69 (2020) 443e449448largely demonstrated. To the best of our knowledge, this is the first
deep intronic variant of SERPING1 gene associated with C1-INH-
HAE that has been reported in the literature. Heretofore, 49
different intronic mutations of SERPING1 gene have been associated
with C1-INH-HAE, all of them located in the donor and acceptor site
or a few nucleotides from these regions4e6,12,25,33e51 (Table 3).
Deleterious deep intronic variants most commonly lead to
pseudo-exon inclusion due to activation of non-canonical splice
sites or changes in splicing regulatory elements, or they can disrupt
transcription regulatory motifs and non-coding RNA genes.7 As far
as the c.-22-155G > T variant is regarded, the most probable sce-
nario indicated by the findings of the in silico and the transcrip-
tional analysis, is that it affects splicing and alters the transcribed
RNA. The mutant mRNA is susceptible to degradation by mRNA
surveillance pathways. Consequently, only the wild type allele is
translated, and this results in C1-INH deficiency.
In more detail, by the use of the NNSPLICE, NetGene2 and
FSPLICE, ASSP bioinformatics tools, it has been shown that the c.-
22-155G > T variant introduces in the genome a new donor site
stronger than the wild type leading to a larger exon 1 in the RNA
level (Fig. 3). This was confirmed by HSF indicating, in parallel, that
the variant disrupts an ISS recognized by a number of transcrip-
tional factors and, as a result, stops the suppression of the intronic
cryptic donor site. Additionally, by analyzing both thewild type and
themutated sequence, SpliceAid 2 concluded that different splicing
motifs are destroyed, including the splicing motifs for the tran-
scriptional factors hnRNP H1, hnRNP H2, hnRNP F, hnRNP H3which
act as silencers in the wild type sequence. Transcriptional analysis
confirmed that the mutant mRNA is susceptible to degradation. To
this aim, an informative exonic SNP, i.e. the polymorphism rs4926
(c.1438G > A) carried by the patients in heterozygous state, was
used. On the RNA level, this polymorphism was found in homo-
zygous state, which indicates that the mutated allele is degraded,
obviously through mRNA surveillance pathways. Further studies
are required in order to define which of the three translation-
associated mRNA surveillance pathways (nonsense-mediated
mRNA decay, no-go decay, nonstop decay) that target mRNAs for
degradation is involved.7
In favor of the pathogenicity of the c.-22-155G > T variant is its
location in a chromosomal region of intron 1 which, by the use of
GERP, a statistically rigorous and biologically transparent frame-
work for constrained element identification,27 was found highly
conserved. Generally, it is considered that the first intron is highly
conserved and that its conservation is related to its enrichment
with regulatory elements28 and a specific pattern of chromatin
organization.29 However, the first intron of SERPING1 is not the
longest among all other downstream introns within the gene as it
happens in most species.30
In conclusion, our study verified the earlier hypothesis that
intronic alterations could be the cause of the disease in cases of C1-INH-HAE where standard genotyping approaches cannot uncover
any DNA damage, highlighting one more advantage of NGS8 in the
molecular analysis of these patients.31 Therefore, advanced DNA
sequencing methods should be performed in cases of C1-INH-HAE
where standard approaches fail to uncover the genetic alteration.
Finally, despite that one fifth of SERPING1 intronic length is
escaping the analysis by our NGS panel, the possibility of intronic
alterations to be the invisible damage whenever standard geno-
typing cannot detect the cause of C1-INH-HAE, is minimized. The
regulatory mechanisms of gene expression comprise diverse mo-
lecular circuits involving multiple dedicated components. Thus
mechanisms intervening to the expression of SERPING1, other than
alterations in non-coding regions, should be considered. As Dirk A.
Kleinjan and Veronica van Heyningen have noted32: “… the labo-
rious identification of the disease loci and regulatory mechanisms
involved in currently ‘unsolved’ human disorders remains a huge
but rewarding task”.Conflict of interest
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